Alexander Kristian
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Mono- and multimeric PSMA-targeting small molecule-thorium-227 conjugates for optimized efficacy and biodistribution in preclinical models.
Journal: European journal of nuclear medicine and molecular imaging
Published: May 26, 2023
A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.
Journal: Molecular cancer therapeutics
Published: January 18, 2023
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.
Journal: Frontiers in medicine
Published: August 31, 2022
89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 19, 2021
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: September 18, 2019
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 12, 2019
Influx rate of 18F-fluoroaminosuberic acid reflects cystine/glutamate antiporter expression in tumour xenografts.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 27, 2019
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Journal: International journal of radiation oncology, biology, physics
Published: November 30, 2018
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 21, 2018
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 24, 2018
Showing 1-12 of 12
Last Updated: 09/26/2026